T1	Participants 359 367	Children
T2	Participants 568 576	Children
T3	Participants 600 688	treatment with placebo, albendazole (ALB), diethylcarbamazine (DEC), or combined therapy
T4	Participants 709 716	DEC/ALB
T5	Participants 815 822	DEC/ALB
T6	Participants 799 818	Albendazole and DEC
T7	Participants 975 990	ALB and DEC/ALB
T8	Participants 1157 1165	children
T9	Participants 1200 1207	DEC/ALB
T10	Participants 1232 1235	DEC
T11	Participants 1067 1090	Albendazole and DEC/ALB
T12	Participants 519 527	children
